Therefore, without affecting immunotherapy efficacy, IL-6 blockade (tocilizumab), IL-1 blockade (anakinra), and TNF-α blockade (infliximab) may be possible approaches to treat steroid-refractory CIP. This evidence concerns the gene IL1B and hereditary sensory and autonomic neuropathy.